Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Cancer02:18

Cancer

55.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-institution experience of 500 consecutive pancreatoduodenectomies: case-matched outcomes of the da Vinci Xi robotic versus open procedures.

Surgical endoscopy·2026
Same author

Fluid shear stress enhances pancreatic cancer motility through YAP activation.

Clinical epigenetics·2026
Same author

The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

The multidimensional signature of oxysterols: Comparative RPLC-HRMS-based profiling of healthy and pancreatic tumour cell lines.

Talanta·2026
Same author

The Neutrophil-NET Axis in Immune Checkpoint Inhibitor Resistance in Non-Small Cell Lung Cancer: Roles, Biomarkers and Therapeutic Opportunities.

Biomolecules·2026
Same author

The Role of the Ecto-Nucleotidases CD73 and CD39 in Chemo- and Immunotherapy.

Cancers·2026
Same journal

<i>ARID1A</i> Expression is Down-Regulated by Oxidative Stress in Endometriosis and Endometriosis-Associated Ovarian Cancer.

Translational oncogenomics·2017
Same journal

The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.

Translational oncogenomics·2016
Same journal

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics.

Translational oncogenomics·2016
Same journal

Interplay Between Metabolism and Oncogenic Process: Role of microRNAs.

Translational oncogenomics·2016
Same journal

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.

Translational oncogenomics·2015
Same journal

Genomic Analysis of the BMP Family in Glioblastomas.

Translational oncogenomics·2015
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.5K

c-Met as a Target for Personalized Therapy.

Ingrid Garajová1, Elisa Giovannetti2, Guido Biasco3

  • 1Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands. ; Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Translational Oncogenomics
|December 3, 2015
PubMed
Summary
This summary is machine-generated.

The HGF-MET pathway drives cancer growth and resistance to targeted therapies. This review covers its role in cancer and therapeutic strategies, including inhibitors targeting HGF and MET signaling.

Keywords:
HGFMETNSCLCdrug resistancepancreatic cancerrenal cancertargeted therapy

More Related Videos

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.4K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Related Experiment Videos

Last Updated: Mar 29, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.5K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.4K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The HGF-MET signaling pathway plays crucial roles in physiological and pathological processes.
  • Dysregulation of this pathway is implicated in cancer development and progression.
  • MET signaling influences cell proliferation, survival, and invasion.

Purpose of the Study:

  • To review the role of the HGF-MET signaling pathway in cancer.
  • To summarize current therapeutic strategies targeting HGF-MET.
  • To discuss the pathway's role in acquired resistance to targeted anticancer therapies.

Main Methods:

  • Literature review of scientific articles on HGF-MET signaling in cancer.
  • Analysis of downstream signaling pathways including MAPK, PI3K/AKT, STAT, and NF-κB.
  • Examination of therapeutic agents targeting HGF and MET.

Main Results:

  • HGF-MET signaling is a key oncogenic driver and a mechanism of resistance to EGFR and VEGFR inhibitors.
  • Targeting HGF-MET with inhibitors shows therapeutic potential in various cancers.
  • The pathway's involvement in resistance is evident in lung, kidney, and pancreatic cancers.

Conclusions:

  • The HGF-MET pathway is a significant therapeutic target in oncology.
  • Understanding HGF-MET signaling is critical for overcoming resistance to targeted cancer treatments.
  • Further research into HGF-MET inhibitors may lead to improved cancer therapies.